Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily
Results for TAK-279 (Formerly NDI-034858) Show a Significantly Greater Proportion of Patients Achieved Psoriasis Area and Severity Index (PASI) 75 at Doses ≥5mg at 12 Weeks1At the Highest Dose of TAK-279, 46% of Patients Achieved PASI 90 and 33% Achieved PASI 100 at 12 Weeks, Indicating a Near-Total or Total Clearan...
United States New Orleans April Armstrong Mark Dole Christopher Oreilly American Academy Of Dermatology Association
Source: pharmiweb.com